Summary
Other Scenarios:
- SRA - JNJ
- SRA - RHHBY
- JNJ - BRL
- RHHBY - BRL
| Buyer: | Merck Serono S.A. (ADR) (SRA) | Last Price: | 22.72 | Market Cap.: | 13.92B |
|---|---|---|---|---|---|
| Target: | Barr Pharmaceuticals, Inc. (BRL) | Last Price: | 54.70 | Market Cap.: | 6.00B |
Lines of Business Summary:
- Merck Serono S.A. (ADR) (SRA) competes in 1 industry and 35 product/service groups
- Barr Pharmaceuticals, Inc. (BRL) competes in 1 industry and 224 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- Merck Serono S.A. (ADR) (SRA) has 3 and Barr Pharmaceuticals, Inc. (BRL) has 0 suppliers that rely on a material % of their business. They share 0 in common.
- Merck Serono S.A. (ADR) (SRA) has 0 and Barr Pharmaceuticals, Inc. (BRL) has 4 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
*Healthcare |
|
|
879 |
Biopharmaceuticals |
|
|
337 |
|
Medical Devices |
|
|
247 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 38)
|
Target (Total: 155)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 13)
|
Target (Total: 3)
|
Buyer (Total: 6)
|
Target (Total: 7)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 4,775 | 8,500 |
| Revenue Per Employee | 620,306.2 | 282,835.1 |
| Total Revenue | 739.2 | 599.4 |
| Total Expenses | 605.3 | 547.7 |
Other Revenue
|
83.6 | 35.6 |
|
Cost of Revenue
|
84.9 | 302.5 |
|
SG&A Expense
|
283.0 | 182.4 |
|
Research & Development
|
165.9 | 61.2 |
|
Other Operating Expense
|
71.4 | 0.0 |
|
Operating Income
|
134.0 | 51.7 |
|
Unusual Income
|
0.0 | 1.5 |
|
LT Debt to Capital
|
0.75 | 55.64 |
|
Fwd P/E
|
n/a | 17.93 |
|
Fwd P/Rev
|
n/a | 2.41 |
| Book Value | 3,682.9 | 1,498.8 |
|
Curr Portion of LTD/Cap Lease
|
0.0 | 650.9 |
Individual Company Summary
Focused
Buyer
Focused ():
*Healthcare > Biopharmaceuticals > Neurology
Target
Focused ():
*Healthcare > Biopharmaceuticals
Business Description
Buyer
Merck Serono S.A., formerly Serono S.A. is a biotechnology company that discovers, develops, manufactures and markets therapeutic products for the treatment of human diseases in selected therapeutic areas. It focuses on specialized markets of neurology, reproductive health, growth and metabolism, dermatology, oncology and autoimmune diseases and has eight biotechnology products on the market. The Company has a global presence with operations in more than 40 countries, main production facilities in four countries and sales in over 90 countries. As of December 31, 2006, the Company had approximately 25 ongoing development projects, based on proteins, monoclonal antibodies and small molecules. In January 2007, Merck KGaA acquired majority interest in Serono S.A.
Target
Barr Pharmaceuticals, Inc. is primarily a holding company. The Company's subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceutical products, respectively. It operates in two business segments. In the generic pharmaceutical segment, it manufactures and distributes approximately 150 different dosage forms and strengths of approximately 75 different generic pharmaceutical products, including 22 oral contraceptive products that represent the largest category of its generic product portfolio. In the proprietary pharmaceutical segment, the Company manufactures and distributes 19 proprietary pharmaceutical products, largely concentrated in the women's healthcare therapeutic category. These products include SEASONALE and SEASONIQUE extended-cycle oral contraceptive products, and Cenestin (synthetic conjugated estrogens, A) and ENJUVIA (synthetic conjugated estrogens, B) line of hormone therapy products.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
89.38 | 57.2 |
|
Operating Margin %
|
26.26 | -3.19 |
|
Quick Ratio
|
1.69 | 1.27 |
|
Current Ratio
|
2.38 | 1.83 |
|
Coverage Ratio
|
0.04 | 0.69 |
| Total Assets | 5,601.4 | 4,799.4 |
| Return on Equity % | 19.97 | -16.22 |
| Return on Assets % | 13.13 | -5.07 |
|
Cash+ ST Inv. Per Share
|
3.46 | 7.79 |
| Total Debt | 804.7 | 2,530.8 |
| Total Debt to Equity % | 21.85 | 168.85 |
| Total Debt to Tangible Equity % | 23.91 | n/a |
|
Debt to Asset %
|
14.37 | 52.73 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
|
|
|
|
Medical Devices |
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
|
|
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes medical devices that diagnose and treat female reproductive diseases; devices used to care for women during pregnancy, childbirth, and the post-partum period are also included in this sector.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Dermatology |
|
|
|
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit the inflammation by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation preventingcyclooxygenase activity.
Target Products:
|
|
|
|
Systemic |
|
|
|
Anaphylactic Shock |
|
|
|
Adjunctive Treatments |
|
|
|
Antihistamines/Antiserotonins
Therapeutics that assist the primary treatment of a life-threatening systemic allergic reaction resulting from secondary or subsequent exposure to a foreign substance by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Upper Respiratory |
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.
Target Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Angina |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Arrhythmia |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.
Target Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the release of fatty acids from adipose tissue.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.
Target Products:
|
|
|
|
Vascular Disorders |
|
|
|
Aneurysms |
|
|
|
Hemorrhage |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat bleeding from aneurysms by blocking the flow of calcium ions from the blood vessel wall.
Target Products:
|
|
|
|
Atherosclerosis |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat the narrowing or hardening of arteries by inhibiting the release of fatty acids from adipose tissue.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.
Target Products:
|
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.
Target Products:
|
|
|
|
Hypertension |
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat high blood pressure by blocking alpha adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.
Target Products:
|
|
|
|
Peripheral Vascular Disease |
|
|
|
Blood Viscosity Reducing Agents
Therapeutics that treat arterial obstruction outside of the heart by altering the flow of red blood cells.
Target Products:
|
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat arterial obstruction outside of the heart by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Thromboembolism |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Phosphodiesterase Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing platelets from clumping together.
Target Products:
|
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Target Products:
|
|
|
|
Tremors |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that prevent or treat involuntary trembling by blocking the beta adrenergic receptors in muscle tissue.
Target Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Vulgaris |
|
|
|
Antibacterial Agents |
|
|
|
Macrolides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting RNA-dependent bacterial protein synthesis.
Target Products:
|
|
|
|
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Target Products:
|
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.
Target Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Chronic Urticaria |
|
|
|
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.
Target Products:
|
|
|
|
Pruritus |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Psoriasis |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat a slow growing, chronic inflammatory skin disorder characterized by dry, scaling patches by inhibiting an enzyme needed for the synthesis of DNA.
Target Products:
|
|
|
|
Immunosuppressants
Therapeutics that treat a slow growing, chronic inflammatory skin disorder characterized by dry, scaling patches by suppressing the immune system.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Gastric |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Acid Indigestion/Heartburn |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.
Target Products:
|
|
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat Gastroesophageal Reflux Disease (GERD) by blocking dopamine receptor and stimulating gastrointestinal movement without stimulating secretions from the pancreas, stomach or gall bladder.
Target Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Gastroparesis |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat gastroparesis by blocking the action of dopamine.
Target Products:
|
|
|
|
Nausea/Vomiting |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.
Target Products:
|
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Target Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Intestinal Intubation |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that cause bowel evacuation prior to intubation by blocking the action of dopamine.
Target Products:
|
|
|
|
Short Bowel Syndrome |
|
|
|
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development to treat a disorder resulting from operative resection of the intestines leading to impaired absorption and digestion in the intestines.
Buyer Products:
|
|
|
|
Liver Disorders |
|
|
|
Cirrhosis |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Target Products:
|
|
|
|
Hepatitis |
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Adrenal Gland Disorders |
|
|
|
Adrenocortical Insufficiency |
|
|
|
Synthetic Adrenocortical Steroids
Therapeutics that treat Adrenocortical Insufficiency by acting on the distal tubules
of the kidney to enhance the reabsorption of sodium ions and to increase the urinary excretion of both potassium and hydrogen ions.
Target Products:
|
|
|
|
Diabetes |
|
|
|
Induced Complications |
|
|
|
Central Diabetes Insipidus |
|
|
|
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.
Target Products:
|
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.
Target Products:
|
|
|
|
Biguanides/Insulin Stimulating Agents
Therapeutics that control high blood sugar by stimulating the release of insulin as well as decreasing the production of glucose in the liver.
Target Products:
|
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Target Products:
|
|
|
|
General Hormone Treatments |
|
|
|
Estrogens
Therapeutics that treat hormonal disorders by providing estrogen.
Target Products:
|
|
|
|
Prednisolones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Gout |
|
|
|
Gouty Arthritis |
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Target Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys.
Target Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.
Target Products:
|
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat elevated cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.
Target Products:
|
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Pituitary Gland Disorders |
|
|
|
Lipodystrophy |
|
|
|
Growth Hormones
Therapeutics that treat lipodystrophy by providing a hormone which stimulates body growth and development.
Buyer Products:
|
|
|
|
Severe Short Stature |
|
|
|
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.
Buyer Products:
|
|
|
|
Turner`s Syndrome |
|
|
|
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.
Buyer Products:
|
|
|
|
Reproductive Disorders |
|
|
|
Amenorrhea |
|
|
|
Progestins
Female sex hormone necessary for the development of the female reproductive system.
Buyer Products:
Target Products:
|
|
|
|
Menopause |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Target Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that are mixture of two female sex hormones that are important for the development of the female reproductive system.
Target Products:
|
|
|
|
Progestins
Therapeutics that are female sex hormones.
Target Products:
|
|
|
|
Hematology |
|
|
|
Hemophilia |
|
|
|
Hemophilia A |
|
|
|
Antidiuretic Agents
Therapeutics that treat prevent the loss of water in the urine.
Target Products:
|
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
|
Anemia |
|
|
|
Folic Acid Derivatives
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues caused by folic acid deficiency.
Target Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.
Target Products:
|
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.
Target Products:
|
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that prevents the resorption of urate within the kidneys.
Target Products:
|
|
|
|
Hypokalemia |
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat hypokalemia by promoting excretion while inhibiting the removal of potassium.
Target Products:
|
|
|
|
Thrombocyte (Platelet) Disorders |
|
|
|
Thrombocythemia |
|
|
|
Megakaryocyte Maturation Inhibitors
Therapeutics that prevents the maturation of platelet producing cells.
Target Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Target Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the action of the dihydrofolate enzyme.
Target Products:
|
|
|
|
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.
Target Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat chronic inflammation of the joints by inhibiting a full immune response.
Target Products:
|
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Adenosine Deaminase Inhibitors
Therapeutics that treat multiple sclerosis by inhibiting the transformation of deoxyadenosine into deoxyinosine, thereby impairing the proliferation of certain white blood cells.
Buyer Products:
|
|
|
|
Interferons
Therapeutics that treat multiple sclerosis with a recombinant human protein that downregulates the antibody response of the immune system.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat a neurodegenerative disease characterized by the gradual accumulation of plaques on the nerve sheaths an enzyme that inhibits the proliferation of cells.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat a chronic autoimmune disease characterized by thickened skin with silver scales by blocking the action of the dihydrofolate enzyme.
Target Products:
|
|
|
|
Immunosuppressants
Therapeutics that treat a chronic autoimmune disease characterized by thickened skin with silver scales by inhibiting a full immune response.
Target Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Hereditary Angioedema |
|
|
|
Gonadotropin Inhibitors
Therapeutics that treat swelling under the skin caused by the absence of an essential immune regulator by increasing levels of C4 complement component.
Target Products:
|
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.
Target Products:
|
|
|
|
Nitroimidazoles
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and causing cell death.
Target Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Otitis Media |
|
|
|
Macrolides/Sulfonamides
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting RNA-dependent bacterial protein synthesis and by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Pneumonia |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Respiratory Tract Infections |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Tuberculosis |
|
|
|
Antitubercular Agents
Therapeutics that treat a bacterial infection of the lung by inhibiting bacterial and mycobacterial RNA synthesis.
Target Products:
|
|
|
|
Systemic |
|
|
|
Leprosy |
|
|
|
Erythema Nodosum Leprosum (ENL) |
|
|
|
Immunomodulatory Agents
Therapeutics that treat a bacterial infection characterized by the formation of tender, red nodules on the front of the legs by stimulating the immune system.
Target Products:
|
|
|
|
Urology |
|
|
|
Prostatitis |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Broad Spectrum |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Triazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Candidiasis |
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the skin caused by yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Mucous |
|
|
|
Candidiasis |
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the secretory lining of the tissues caused by a yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Target Products:
|
|
|
|
Nervous System |
|
|
|
Cryptococcal Meningitis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Esophageal Candidiasis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Oropharyngeal Candidiasis |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the mouth and pahrynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the mucosa caused by yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Target Products:
|
|
|
|
Urology |
|
|
|
Vaginal Candidiasis |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Broad Spectrum |
|
|
|
Nitroimidazoles
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Malaria |
|
|
|
Aminoquinolines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by inhibiting parasite growth.
Target Products:
|
|
|
|
Viral |
|
|
|
RNA Viruses |
|
|
|
Flavivirus |
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Osteoporosis |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Target Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Target Products:
|
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
|
Gouty Arthritis |
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Target Products:
|
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Target Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the action of the dihydrofolate enzyme.
Target Products:
|
|
|
|
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.
Target Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat rheumatoid arthritis by suppressing the immune system.
Target Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Alzheimer`s Disease |
|
|
|
Acetylcholinesterase Inhibitors/Nicotinic Receptor Modulators
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine, and by modulating the receptor that binds nicotine.
Target Products:
|
|
|
|
Epilepsy |
|
|
|
Partial Seizures |
|
|
|
Complex |
|
|
|
Adjunctive Therapy |
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Target Products:
|
|
|
|
Simple |
|
|
|
Adjunctive Therapy |
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Target Products:
|
|
|
|
Primary Generalized Seizures |
|
|
|
Absence (Petit Mal) |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat Petit Mal Seizures by preventing the entrance of calcium into nerve cells.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Akinetic Pattern |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic
Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Myoclonic |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Tonic-Clonic (Grand Mal) |
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Target Products:
|
|
|
|
Headaches |
|
|
|
Tension Type |
|
|
|
Analgesics/Sedatives/Vasoconstrictive Agents
Therapeutics that treat tension type headaches by inhibiting the action of prostaglandins, constricting blood vessels in the brain thus reducing the pulsing action of blood in the cerebral arteries, and exerting a mild sedative effect.
Target Products:
|
|
|
|
Vascular (Migraine) |
|
|
|
Acute Treatments |
|
|
|
Analgesics/Sedatives/Vasoconstrictive Agents
Therapeutics that treat migraine by inhibiting the action of prostaglandins, constricting blood vessels in the brain thus reducing the pulsing action of blood in the cerebral arteries, and exerting a mild sedative effect.
Target Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat Migraine by inhibiting stimulation of beta adrenergic receptors.
Target Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Adenosine Deaminase Inhibitors
Therapeutics that treat multiple sclerosis by inhibiting the transformation of deoxyadenosine into deoxyinosine, thereby impairing the proliferation of certain white blood cells.
Buyer Products:
|
|
|
|
Interferons
Therapeutics that treat multiple sclerosis with a recombinant human protein that down regulates the antibody response of the immune system.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat multiple sclerosis by inhibiting a key enzyme involved with cell division.
Buyer Products:
|
|
|
|
Myasthenia Gravis (MG) |
|
|
|
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.
Target Products:
|
|
|
|
Parkinson`s Disease (PD) |
|
|
|
Adjunctive Treatments |
|
|
|
Cholinergic Receptor Blocking Agents
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by blocking acetylcholine receptors on neurons.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Antihistamines
Therapeutics that treat anxiety by blocking the action of histamines.
Target Products:
|
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat anxiety by blocking dopamine receptors.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Obsessive Compulsive Disorder (OCD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Panic Disorder |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Post-Traumatic Stress Disorder (PTSD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat post traumatic stress disorder by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Social Anxiety Disorder (SAD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Childhood/Adolescent Disorders |
|
|
|
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
|
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hyperactivity in children due to an abnormally short attention span.
Target Products:
|
|
|
|
Enuresis (Bedwetting) |
|
|
|
Antidiuretic Agents
Therapeutics that treat enuresis by suppressing the passing of urine.
Target Products:
|
|
|
|
Eating Disorders |
|
|
|
Bulimia |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat eating disorders by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Mood Disorders |
|
|
|
Bipolar Disorders (Manic Depressive Disorders) |
|
|
|
Lithium-Based Agents
Therapeutics that treat bipolar disorders by decreasing the concentrations of neurotransmitters.
Target Products:
|
|
|
|
Monoaminergic Antagonists
Therapeutics that treat bipolar disorder by blocking the serotonin and dopamine receptors.
Target Products:
|
|
|
|
Depression |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Tetracyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine.
Target Products:
|
|
|
|
Premenstrual Dysphoric Disorders |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat premenstrual dysphoric disorders by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Schizophrenia |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.
Target Products:
|
|
|
|
Monoaminergic Antagonists
Therapeutics that treat schizophrenia by blocking the serotonin and dopamine receptors.
Target Products:
|
|
|
|
Sleep Disorders |
|
|
|
Insomnia |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Narcolepsy |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat narcolepsy by stimulating the adrenergic receptors, which causes nervous system stimulation.
Target Products:
|
|
|
|
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hronic and sudden daytime sleepiness.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Child Birth/Pregnancy |
|
|
|
Prevention (Contraception) |
|
|
|
Contraceptives (Birth Control) |
|
|
|
Estrogens
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Target Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Target Products:
|
|
|
|
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system
Target Products:
|
|
|
|
Female Genital Disorders |
|
|
|
Endometriosis |
|
|
|
Gonadotropin Inhibitors
Therapeutics that treat endometriosis by preventing the release of the pituitary gland hormone, gonadotropin.
Target Products:
|
|
|
|
Infertility |
|
|
|
Complications |
|
|
|
Premature Ovulation |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Antagonists
Therapeutics that prevent premature ovulation by blocking the action of gonadotropin releasing hormone, which can stimulate ovulation.
Buyer Products:
|
|
|
|
Hormonal Treatments |
|
|
|
Gonadotropins
Therapeutics that treat difficulties in conceiving by stimulating sex hormone secretion from the female gonads.
Buyer Products:
|
|
|
|
Ovulation Stimulating Agents
Therapeutics that treat infertility by stimulating the ovaries to release a mature egg.
Buyer Products:
|
|
|
|
Progestins
Therapeutics that treat female disorders characterized by the inability to achieve pregnancy or carry a pregnancy to term by increasing progesterone level in the body to induce uteran conditions favorable to conception and pregnancy.
Buyer Products:
|
|
|
|
Ovarian |
|
|
|
Hypogonadism |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
These are female sex hormones.
Target Products:
|
|
|
|
Vulvovaginal |
|
|
|
Atrophy |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.
Target Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that treat disorders characterized by thinning of the vaginal walls with a combination of the female sex hormones estrogen and progestin.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Localized |
|
|
|
Antimetabolite Agents |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage breast cancers by inhibiting an enzyme needed for the synthesis of DNA.
Target Products:
|
|
|
|
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancers by blocking the uptake of estrogen which has been implicated in causing breast cancer.
Target Products:
|
|
|
|
Progestins
Therapeutics that treat and manage breast cancers by providing progestins which in turn results in decreased estrogen levels.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancer by blocking the uptake of estrogen which has been implicated in causing breast cancer.
Target Products:
|
|
|
|
Dermatology |
|
|
|
Malignant Melanoma |
|
|
|
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage cancers of pigment cells in the epidermis and dermis by interfering with DNA synthesis.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Colon Cancer/Colorectal Cancer |
|
|
|
Palliative Agents |
|
|
|
Folic Acid Derivatives
Therapeutics that treat colorectal cancers by helping to reduce toxicity by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.
Target Products:
|
|
|
|
Head/Neck Cancer |
|
|
|
Localized |
|
|
|
Antimetabolite Agents |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage primary tumors of the head and neck by inhibiting the production of DNA.
Target Products:
|
|
|
|
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage primary tumors of the head and neck by interfering with DNA synthesis.
Target Products:
|
|
|
|
Hematology |
|
|
|
Leukemia (White Blood Cell Cancer) |
|
|
|
Lymphoid |
|
|
|
Acute |
|
|
|
Lymphocytic |
|
|
|
Antimetabolite Agents |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of lymphocytic cells by inhibiting an enzyme needed for the synthesis of DNA.
Target Products:
|
|
|
|
Meningeal |
|
|
|
Antimetabolite Agents |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage neoplasm's of immature immune cells that have spread to the brain by inhibiting an enzyme needed for the synthesis of DNA.
Target Products:
|
|
|
|
Myeloid |
|
|
|
Chronic |
|
|
|
Myelogenous (CML) |
|
|
|
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by interfering with DNA synthesis.
Target Products:
|
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
|
Cutaneous T-Cell (CTCL) |
|
|
|
Mycosis Fungoides |
|
|
|
Monoclonal Antibodies
Therapeutics that treat T-cell lymphomas by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Non-Hodgkin`s Lymphoma (NHL) |
|
|
|
Antimetabolite Agents |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage lymphomas of B-cells and T-cells by inhibiting the production of DNA.
Target Products:
|
|
|
|
Multiple Myeloma (Plasma Cell Cancer) |
|
|
|
Immunomodulatory Agents
Therapeutics that treat multiple myeloma by stimulating the immune system.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Bone Cancer |
|
|
|
Osteosarcoma |
|
|
|
Palliative Agents |
|
|
|
Folic Acid Derivatives
Therapeutics that are meant to reduce the toxicity of treating malignant tumors of the bone by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Endometrial Cancer |
|
|
|
Localized |
|
|
|
Progestins
Therapeutics that treat and manage cancer of the endometrial cells lining the uterus by providing a female sex hormone necessary for the development of the female reproductive system.
Target Products:
|
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
Metastatic |
|
|
|
Hormonal Treatments |
|
|
|
Progestins
Therapeutics that treat and manage renal cancers that have spread beyond their original tumor site by supplying a female sex hormone necessary for the development of the female reproductive system.
Target Products:
|
|
|
|
Ovarian Cancer |
|
|
|
Adenocarcinoma |
|
|
|
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage cancer of cells lining the ovary by interfering with DNA synthesis.
Target Products:
|
|
|
|
Prostate Cancer |
|
|
|
Localized |
|
|
|
Androgen Receptor Blockers
Therapeutics that treat prostate cancer by blocking androgen receptors. This limits the action of male hormones which have been implicated as a causative agent in prostate cancer.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Androgen Receptor Blockers
Therapeutics that treat and manage prostate cancers that have spread beyond their original tumor site by binding to the androgen receptors in target tissue thus inhibiting the action of androgens.
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Glaucoma |
|
|
|
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.
Target Products:
|
|
|
|
Irritation/Inflammation |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
General (Systemic) |
|
|
|
Adjunctive |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Narcotics |
|
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Target Products:
|
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Target Products:
|
|
|
|
Non-Narcotics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
|
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Prophylactic Treatments |
|
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.
Target Products:
|
|
|
|
Bronchitis |
|
|
|
Prophylactic Treatments |
|
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.
Target Products:
|
|
|
|
Emphysema |
|
|
|
Prophylactic Treatments |
|
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.
Target Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Antitussives
Therapeutics that relieve or prevent coughs.
Target Products:
|
|
|
|
Decongestants/Expectorants/Opioids
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing coughs and help in ejection of mucous.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the inflammation in the upper respiratory tract with steroidal compounds.
Target Products:
|
|
|
|
Surgery |
|
|
|
Cardiovascular System |
|
|
|
Thrombosis |
|
|
|
Thrombin Inhibitors
Therapeutics that thin the blood of a blocked blood vessel during surgery by blocking an enzyme involved in the clotting process.
Target Products:
|
|
|
|
General |
|
|
|
Complications |
|
|
|
Nausea/Vomiting |
|
|
|
Serotonin Receptor Antagonists
Therapeutics that prevent or treat post surgical nausea and vomiting by blocking the receptors that bind serotonin, a neurotransmitter.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Ocular Inflammation |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation resulting from surgical procedures to remove cataracts by preventing cyclooxygenase activity.
Target Products:
|
|
|
|
Toxicology |
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Alcohol |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Target Products:
|
|
|
|
Opioid Antagonists
Therapeutics that treat alcohol dependence by blocking the effect of opioids.
Target Products:
|
|
|
|
Narcotics |
|
|
|
Opioid Antagonists
Therapeutics that treat narcotic addiction by blocking the effect of opioids.
Target Products:
|
|
|
|
Transplantation |
|
|
|
Heart |
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that help manage and suppress the response of the immune system to foreign tissue.
Target Products:
|
|
|
|
Hepatic (Liver) |
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Target Products:
|
|
|
|
Renal (Kidney) |
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Target Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
5-Alpha Reductase Inhibitors
Therapeutics that inhibit the transformation of testosterone into dihydrotestosterone (DHT), a substance that causes enlargement of the prostate.
Target Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Target Products:
|
|
|
|
Testicular |
|
|
|
Hypogonadism |
|
|
|
Gonadotropins
Therapeutics that treat hypogonadism by providing gonadotropins which stimulate sex hormone secretion from the gonads.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Neurogenic Bladder Disease |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Target Products:
|
|
|
|
Cholinergic Agents
Therapeutics that treat bladder dysfunction arising from the malfunction of autonomic nerves that control bladder function with choleinergic agents.
Target Products:
|
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
|
Anticholinergic Agents
Therapeutics that treat the inability to control urinary excretory functions by blocking the actions of choline and other cholinergic agents.
Target Products:
|
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Target Products:
|
|
|
|
Weight Management |
|
|
|
Anorexia (Appetite Loss) |
|
|
|
Progestins
Therapeutics that treat weight loss and other conditions arising from the uncontrolled loss of appetite by administration of hormone progestins.
Target Products:
|
|
|
|
Cachexia |
|
|
|
Anabolic Testosterone Analogs
Therapeutics containing a class of compounds that boost the body's metabolism and help in gaining weight.
Target Products:
|
|
|
|
Growth Hormones
Therapeutics that treat weight loss usually resulting from cancer and/or AIDS treatment by providing a hormone which stimulates body growth and development.
Buyer Products:
|
|
|
|
Progestins
Therapeutics that treat cachexia by providing female hormones.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Medical Devices |
|
|
|
Drug Delivery |
|
|
|
Percutaneous (Subcutaneous/Intramuscular/Intravenous) |
|
|
|
Syringes |
|
|
|
Specialty |
|
|
|
Prefillable
Syringes designed for the advanced loading and storage of medications prior to use
Buyer Products:
|
|
|
|
Transdermal |
|
|
|
Needle Free Injection Systems
Medical devices which generate a highly-pressurized jet of medication for direct delivery through the skin; also known as jet-injectors
Buyer Products:
|
|
|
|
General Surgery |
|
|
|
Invasive |
|
|
|
Transplantation |
|
|
|
Organ Preservation
Devices used to preserve organs prior to transplantation.
Target Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Treatment |
|
|
|
Procedure Specific |
|
|
|
Contraception |
|
|
|
Intrauterine Devices (IUD)
IUDs, or Intrauterine devices, are a form of birth control used by women.
Target Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Roche Holding Ltd. (ADR)
|
|
n/a | 160,264.110 | 24.51 | 21.03 | 4.59 | 4.01 | 6.88 | |
|
Novartis AG (ADR)
|
|
n/a | 132,695.720 | 24.32 | 16.91 | 3.48 | 3.56 | 3.28 | |
|
Wyeth
|
|
n/a | 75,840.119 | 17.51 | 16.02 | 3.63 | 3.44 | 7.06 | |
|
Eli Lilly & Co.
|
|
n/a | 67,328.131 | 28.81 | 17.46 | 4.16 | 3.79 | 7.38 | |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 23,784.954 | 12.54 | 18.38 | 2.70 | 2.63 | 17.54 | |
|
Shire plc (ADR)
|
|
n/a | 12,878.614 | 39.05 | 36.38 | 6.73 | 5.78 | 6.63 | |
|
Par Pharmaceutical Companies, Inc
|
|
n/a | 1,016.836 | n/a | 18.55 | 2.00 | 1.36 | 2.92 | |
|
Savient Pharmaceuticals, Inc.
|
|
n/a | 727.512 | 15.00 | -12.46 | 16.37 | n/a | 4.31 | |
| Buyer | |||||||||
|
Pfizer Inc.
|
|
n/a | 192,581.140 | 10.35 | 12.73 | 3.92 | 4.03 | 6.86 | |
|
Roche Holding Ltd. (ADR)
|
|
n/a | 160,264.110 | 24.51 | 21.03 | 4.59 | 4.01 | 6.88 | |
| Target | |||||||||
|
Johnson & Johnson
|
|
n/a | 183,699.702 | 17.80 | 15.53 | 3.32 | 3.00 | 15.70 | |
|
Roche Holding Ltd. (ADR)
|
|
n/a | 160,264.110 | 24.51 | 21.03 | 4.59 | 4.01 | 6.88 | |
|
Novartis AG (ADR)
|
|
n/a | 132,695.720 | 24.32 | 16.91 | 3.48 | 3.56 | 3.28 | |
|
Wyeth
|
|
n/a | 75,840.119 | 17.51 | 16.02 | 3.63 | 3.44 | 7.06 | |
|
Eli Lilly & Co.
|
|
n/a | 67,328.131 | 28.81 | 17.46 | 4.16 | 3.79 | 7.38 | |
|
Amgen, Inc.
|
|
n/a | 62,667.219 | 20.48 | 13.09 | 4.25 | 4.15 | 13.05 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 59,927.581 | 38.39 | 21.43 | 3.38 | 3.05 | 16.40 | |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 23,784.954 | 12.54 | 18.38 | 2.70 | 2.63 | 17.54 | |
|
Shire plc (ADR)
|
|
n/a | 12,878.614 | 39.05 | 36.38 | 6.73 | 5.78 | 6.63 | |
|
Cephalon, Inc.
|
|
n/a | 5,380.536 | 24.86 | 19.95 | 2.92 | 3.00 | 31.12 | |
|
Mylan Laboratories Inc.
|
|
n/a | 4,356.420 | 12.58 | 12.41 | 3.01 | 2.80 | 4.81 | |
|
Warner Chilcott Ltd.
|
|
n/a | 4,279.671 | n/a | 18.18 | 5.31 | 5.04 | n/a | |
|
Watson Pharmaceuticals, Inc.
|
|
n/a | 3,246.100 | n/a | 24.58 | 1.45 | 1.23 | 31.54 | |
|
Dr. Reddy's Laboratories Limited (ADR)
|
|
n/a | 2,514.047 | 18.63 | 15.28 | 1.93 | 1.83 | n/a | |
|
Perrigo Company
|
|
n/a | 1,868.941 | 27.78 | 22.27 | 1.31 | 1.28 | 5.19 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Bioject Medical Technologies Inc.
|
|
27.00% | 19.247 | n/a | n/a | 1.78 | n/a | 3.86 | |
|
Rigel Pharmaceuticals, Inc.
|
|
14.90% | 286.415 | n/a | -4.84 | 8.56 | 9.06 | 3.28 | |
|
Vernalis plc (ADR)
|
|
4.00% | 399.459 | n/a | n/a | 12.26 | n/a | n/a | |
|
Regeneron Pharmaceuticals, Inc.
|
|
n/a | 1,640.404 | n/a | -14.33 | 26.89 | 19.94 | 8.34 | |
|
ZymoGenetics, Inc.
|
|
n/a | 1,022.986 | n/a | -6.67 | 44.15 | 32.60 | 4.85 | |
|
Taleo Corporation
|
|
n/a | 478.282 | n/a | 128.29 | 4.62 | 3.80 | 6.42 | |
|
Ness Technologies, Inc
|
|
n/a | 468.258 | 16.04 | 12.17 | 0.95 | 0.83 | 3.60 | |
|
XOMA Limited
|
|
n/a | 434.514 | n/a | -11.29 | 14.73 | 7.71 | n/a | |
|
Caliper Life Sciences Inc.
|
|
n/a | 236.790 | n/a | -12.05 | 2.08 | 1.65 | 12.68 | |
|
Columbia Laboratories Inc.
|
|
n/a | 120.294 | n/a | n/a | 6.92 | n/a | n/a | |
|
TorreyPines Therapeutics Inc.
|
|
n/a | 112.261 | n/a | n/a | 11.40 | n/a | 2.76 | |
|
Micromet Inc.
|
|
n/a | 77.495 | n/a | -2.51 | 2.81 | 5.28 | 8.86 | |
|
Owen Mumford Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Mack-Cali Realty Corp.
|
|
n/a | 3,084.120 | 23.97 | 13.30 | 3.95 | 4.63 | 1.75 | |
|
Indevus Pharmaceuticals
|
|
n/a | 548.187 | n/a | -8.82 | 10.66 | 8.04 | n/a | |
|
Common Sense Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Roche Holding Ltd. (ADR)
|
|
n/a | 160,264.110 | 24.51 | 21.03 | 4.59 | 4.01 | 6.88 | |
|
Abbott Laboratories
|
|
n/a | 91,543.593 | 59.09 | 20.96 | 4.05 | 4.04 | n/a | |
|
Amgen, Inc.
|
|
n/a | 62,667.219 | 20.48 | 13.09 | 4.25 | 4.15 | 13.05 | |
|
Akzo Nobel N.V. (ADR)
|
|
n/a | 23,296.279 | 14.08 | 16.61 | 1.27 | 1.54 | 5.13 | |
|
Biogen Idec Inc.
|
|
n/a | 15,869.459 | 70.30 | 18.88 | 5.69 | 5.17 | 4.50 | |
|
Columbia University
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
McKesson Corporation
|
|
27.00% | 18,402.914 | 20.16 | 19.02 | 0.20 | 0.18 | 5.88 | |
|
Cardinal Health, Inc.
|
|
15.00% | 27,606.223 | 20.45 | 20.84 | 0.32 | 0.31 | 7.97 | |
|
AmerisourceBergen Corp.
|
|
11.00% | 9,806.312 | 19.89 | 19.77 | 0.15 | 0.15 | 7.05 | |
|
Walgreen Company
|
|
10.00% | 45,622.784 | 23.22 | 21.90 | 0.89 | 0.84 | 4.32 | |
|
Warner Chilcott Ltd.
|
|
n/a | 4,279.671 | n/a | 18.18 | 5.31 | 5.04 | n/a | |
|
Indevus Pharmaceuticals
|
|
n/a | 548.187 | n/a | -8.82 | 10.66 | 8.04 | n/a | |
|
Government - United States
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Abbott Laboratories
|
|
n/a | 91,543.593 | 59.09 | 20.96 | 4.05 | 4.04 | n/a | |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 23,784.954 | 12.54 | 18.38 | 2.70 | 2.63 | 17.54 | |
|
Akzo Nobel N.V. (ADR)
|
|
n/a | 23,296.279 | 14.08 | 16.61 | 1.27 | 1.54 | 5.13 | |
| Buyer | |||||||||
|
Pfizer Inc.
|
|
n/a | 192,581.140 | 10.35 | 12.73 | 3.92 | 4.03 | 6.86 | |
|
Roche Holding Ltd. (ADR)
|
|
n/a | 160,264.110 | 24.51 | 21.03 | 4.59 | 4.01 | 6.88 | |
|
Abbott Laboratories
|
|
n/a | 91,543.593 | 59.09 | 20.96 | 4.05 | 4.04 | n/a | |
|
AstraZeneca plc (ADR)
|
|
n/a | 81,935.278 | 13.26 | 13.57 | 3.01 | 2.92 | 8.66 | |
|
Genentech, Inc.
|
|
n/a | 81,388.978 | 33.94 | 29.34 | 8.03 | 6.96 | 9.71 | |
|
Wyeth
|
|
n/a | 75,840.119 | 17.51 | 16.02 | 3.63 | 3.44 | 7.06 | |
|
Amgen, Inc.
|
|
n/a | 62,667.219 | 20.48 | 13.09 | 4.25 | 4.15 | 13.05 | |
|
Bayer AG (ADR)
|
|
n/a | 52,907.745 | 10.05 | 16.01 | 1.28 | 1.16 | n/a | |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 23,784.954 | 12.54 | 18.38 | 2.70 | 2.63 | 17.54 | |
|
Akzo Nobel N.V. (ADR)
|
|
n/a | 23,296.279 | 14.08 | 16.61 | 1.27 | 1.54 | 5.13 | |
| Target | |||||||||
|
Abbott Laboratories
|
|
n/a | 91,543.593 | 59.09 | 20.96 | 4.05 | 4.04 | n/a | |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 23,784.954 | 12.54 | 18.38 | 2.70 | 2.63 | 17.54 | |
|
Akzo Nobel N.V. (ADR)
|
|
n/a | 23,296.279 | 14.08 | 16.61 | 1.27 | 1.54 | 5.13 | |
|
Shire plc (ADR)
|
|
n/a | 12,878.614 | 39.05 | 36.38 | 6.73 | 5.78 | 6.63 | |
|
Cephalon, Inc.
|
|
n/a | 5,380.536 | 24.86 | 19.95 | 2.92 | 3.00 | 31.12 | |
|
King Pharmaceuticals, Inc.
|
|
n/a | 5,229.016 | 14.76 | 12.45 | 2.59 | 2.53 | 4.46 | |
|
Warner Chilcott Ltd.
|
|
n/a | 4,279.671 | n/a | 18.18 | 5.31 | 5.04 | n/a | |
|
Par Pharmaceutical Companies, Inc
|
|
n/a | 1,016.836 | n/a | 18.55 | 2.00 | 1.36 | 2.92 | |
|
Savient Pharmaceuticals, Inc.
|
|
n/a | 727.512 | 15.00 | -12.46 | 16.37 | n/a | 4.31 | |
|
Indevus Pharmaceuticals
|
|
n/a | 548.187 | n/a | -8.82 | 10.66 | 8.04 | n/a | |
|
Paladin Labs Inc.
|
|
n/a | 176.576 | 33.68 | n/a | 4.04 | n/a | 3.74 | |
|
Common Sense Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 2,498.4 | 1,721.5 | 4,219.9 |
|
Other Revenue
|
306.6 | 145.9 | 452.5 |
| Total Revenue | 2,804.9 | 1,867.4 | 4,672.4 |
|
Cost of Revenue
|
298.0 | 799.2 | 1,097.2 |
|
SG&A Expense
|
954.3 | 540.4 | 1,494.7 |
|
Depreciation & Amortization
|
0.0 | 0.0 | 0.0 |
|
Research & Development
|
560.5 | 205.2 | 765.6 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
255.6 | 0.0 | 255.6 |
|
Unusual Expense (Income)
|
0.0 | 382.2 | 382.2 |
| Total Expenses | 2,068.4 | 1,927.0 | 3,995.3 |
|
Operating Income
|
736.6 | -59.5 | 677.0 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
30.0 | -40.8 | -10.7 |
|
Other, Net
|
0.0 | -55.1 | -55.1 |
| Income Before Taxes | 766.6 | -155.4 | 611.2 |
| Income Taxes | 31.0 | 87.7 | 118.7 |
| Income After Taxes | 735.6 | -243.1 | 492.5 |
| Minority Interest (IS) | -0.2 | -0.9 | -1.1 |
|
Net Income - Excl. Xord. Items
|
735.4 | -244.0 | 491.4 |
| Discontinued Operations | 0.0 | -0.3 | -0.3 |
|
Net Income - Incl. Xord. Items
|
735.4 | -244.3 | 491.1 |
|
Income Avail. to Common
|
735.4 | -244.3 | 491.1 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
595.4 | 106.7 | 702.1 |
|
Basic EPS - Excl. Xord. Items
|
1.24 | n/a | 0.70 |
|
Basic EPS - Incl. Xord. Items
|
1.24 | n/a | 0.70 |
| Full Dilution Adjustment | 10.8 | 0.0 | 10.8 |
| Fully Diluted Shares Outstanding | 602.2 | 108.0 | 710.2 |
|
F.D. EPS - Excl. Xord. Items
|
1.22 | n/a | 0.69 |
|
F.D. EPS - Incl. Xord. Items
|
1.22 | n/a | 0.69 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
1,734.9 | 194.7 | 1,929.6 |
|
ST Investments
|
351.2 | 647.5 | 998.6 |
|
Accounts Receivable
|
439.5 | 512.1 | 951.7 |
|
Inventory
|
254.9 | 428.5 | 683.4 |
|
Prepayments and Advances
|
788.3 | 40.8 | 829.1 |
|
Other Current Assets
|
0.0 | 129.1 | 129.1 |
|
Current Assets
|
3,568.9 | 1,952.7 | 5,521.6 |
|
PPE
|
0.0 | 1,251.0 | 1,251.0 |
|
Accum D&A
|
0.0 | -216.8 | -216.8 |
|
PPE, Net
|
873.5 | 1,034.2 | 1,907.8 |
| Goodwill & Intangibles | 317.3 | 1,714.3 | 2,031.6 |
| Long Term Investments | 474.9 | 11.8 | 486.7 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
366.8 | 86.4 | 453.2 |
| Total Assets | 5,601.4 | 4,799.4 | 10,400.8 |
| Liabilities | |||
| Accounts Payable | 421.9 | 138.7 | 560.6 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 0.0 | 262.9 | 262.9 |
|
ST Debt
|
776.7 | 0.0 | 776.7 |
|
Curr Port of LTD & Cap Lease Oblg
|
0.0 | 650.9 | 650.9 |
| Other (Current) Liabilities | 298.3 | 17.4 | 315.7 |
|
Current Liab.
|
1,496.9 | 1,069.9 | 2,566.8 |
|
LT Debt
|
28.0 | 1,879.9 | 1,907.8 |
|
Total LT Debt
|
28.0 | 1,879.9 | 1,907.8 |
| Minority Interest (BS) | 0.9 | 39.0 | 40.0 |
| Deferred Taxes | 5.6 | 211.3 | 216.9 |
|
Other LT Liab.
|
387.1 | 100.4 | 487.5 |
|
Total Liabilities
|
1,918.5 | 3,300.6 | 5,219.0 |
| Shareholders Equity | |||
| Common Stock | 237.1 | 1.1 | 238.2 |
| Additional Paid in Capital | 817.7 | 624.9 | 1,442.6 |
| Retained Earnings | 2,571.7 | 889.6 | 3,461.3 |
| Treasure Stock | 0.0 | -100.7 | -100.7 |
| Other Equity | 56.3 | 84.0 | 140.3 |
|
Total Equity
|
3,682.9 | 1,498.8 | 5,181.7 |
|
Total Liab. & Equity
|
5,601.4 | 4,799.4 | 10,400.8 |
|
Shares Outstanding
|
612.5 | 106.8 | 719.3 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 735.6 | -66.2 | 669.4 |
| CF Depreciation | 126.5 | 190.7 | 317.2 |
| CF Deferred Taxes | 0.0 | 2.4 | 2.4 |
| Other Non-Cash Items | 101.3 | 469.9 | 571.3 |
| Change in Working Capital | -73.6 | -78.9 | -152.5 |
| Total Cash From Operating Activities | 889.8 | 517.9 | 1,407.7 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -199.7 | -104.2 | -303.9 |
| Other Investing Cash Flows | 742.9 | -2,657.3 | -1,914.4 |
| Total Cash From Investing Activities | 543.2 | -2,761.5 | -2,218.3 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -117.1 | 0.0 | -117.1 |
| Purchase Or Sale of Stock | 41.8 | 62.8 | 104.6 |
| Purchase and Retirement of Debt | 58.4 | 2,255.1 | 2,313.6 |
| Other Financing Cash Flow | -34.0 | 16.4 | -17.6 |
| Total Cash From Financing Activities | -58.6 | 2,334.4 | 2,275.8 |
| Exchange Rate Effects | 1.7 | 3.3 | 5.1 |
| Net Change in Cash | 1,376.1 | 94.2 | 1,470.2 |
| Cash Taxes Paid | 108.7 | 179.5 | 288.2 |
| Cash Interest Paid | 6.5 | 6.6 | 13.1 |